Download PDF
Dtsch Med Wochenschr 2013; 138(40): 2031-2033
DOI: 10.1055/s-0033-1349583
Nephrologie | Commentary
Nephrologie
© Georg Thieme Verlag KG Stuttgart · New York

Primäre und sekundäre glomeruläre Erkrankungen

Primary and secondary glomerular diseases
B. Banas
1   Klinik und Poliklinik für Innere Medizin II – Nephrologie, Universitätsklinikum Regensburg
,
R. Birck
2   Praxis für Nieren- und Hochdruckkrankheiten, Dialysezentren Lindau/Westallgäu, Akademische Lehrpraxis Fakultät für Medizin Mannheim, Universität Heidelberg
› Author Affiliations
Further Information

Publication History

Publication Date:
24 September 2013 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

Glomerulopathie - IgA-Nephropathie - ANCA-assoziierte Vaskulitis (AASV) - Hämolytisch-urämisches Syndrom (HUS)

Keywords

glomerulopathy - IgA nephropathy - ANCA-associated vasculitis - hemolytic-uremic syndrome
 

  • Literatur

  • 1 Berden A, Goceroglu A, Jayne D et al. Diagnosis and management of ANCA associated vasculitis. BMJ 2012; 344: e26
    CrossrefPubMedGoogle Scholar
  • 2 Buchholz U, Bernard H, Werber D et al. German outbreak of Escherichia coli O104:H4 associated with sprouts. N Engl J Med 2011; 365: 1763-1770
    CrossrefPubMedGoogle Scholar
  • 3 Faurschou M, Westman K, Rasmussen N et al. Long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthr Rheum 2012; 64: 3472-3477
    CrossrefPubMedGoogle Scholar
  • 4 Floege J, Feehally J. Treatment of IgA nephropathy and Henoch-Schönlein nephritis. Nat Rev Nephrol 2013; 9: 320-327
    CrossrefPubMedGoogle Scholar
  • 5 Harper L, Morgan MD, Walsh M et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 2012; 71: 955-960
    CrossrefPubMedGoogle Scholar
  • 6 Jennette JC, Falk RJ, Bacon PA et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65: 1-11
    CrossrefPubMedGoogle Scholar
  • 7 Karpman D, Sartz L, Johnson S. Pathophysiology of typical hemolytic uremic syndrome. Seminars in thrombosis and hemostasis 2010; 36: 575-585
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Kielstein JT, Beutel G, Fleig S et al. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dialysis Transplant 2012; 27: 3807-3815
    CrossrefPubMedGoogle Scholar
  • 9 Menne J, Nitschke M, Stingele R et al. Validation of treatment strategies for enterohaemorrhagic Escherichia col. O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 2012; 345: e4565 doi: DOI: 10.1136/bmj.e4565.
    CrossrefPubMedGoogle Scholar
  • 10 NEFIGAN. The NEFIGAN trial. http://www.nefigan.net/ (letzter Zugriff 9.9.2013)
    Google Scholar
  • 11 Smerud HK, Bárány P, Lindström K et al. New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria. Nephrol Dial Transplant 2011; 26: 3237-3242
    CrossrefPubMedGoogle Scholar
  • 12 Specks U, Merkel PA, Seo P et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 2013; 369: 417-4274
    CrossrefPubMedGoogle Scholar
  • 13 STOP IGAN. Supportive versus immunosuppressive therapy for the treatment of progressive IgA nephropathy. http://www.stop-igan-study.rwth- aachen.de/ (letzter Zugriff 9.9.2013)
    Google Scholar